The three reaction types – overview
Many people use "allergy" loosely for all reactions caused by gloves. This is imprecise and can lead to wrong choices. There are three clinically distinct reactions:
| Reaction | Mechanism | Cause | Timing | Severity |
|---|---|---|---|---|
| Irritant contact dermatitis (ICD) | Non-immunological | Moisture, friction, chemicals | During/immediately after use | Variable – rarely severe |
| Type IV allergy (ACD) | T-cell mediated (delayed) | Accelerators and other chemicals | 24–72 hours after contact | Moderate to severe |
| Type I allergy (IgE-mediated) | IgE antibody against protein | Latex proteins (Hev b) | Minutes after contact | Potentially life-threatening (anaphylaxis) |
Irritant contact dermatitis (ICD)
ICD is the most common reaction when using gloves and is not an allergy – it is a mechanical and chemical skin injury.
Mechanism
Gloves create a closed environment: sweat accumulates, skin macerates and barrier integrity is weakened. Additional contributions come from:
- Friction from the glove against the skin
- Detergents and disinfectants that dry out the skin
- Powder in older gloves (now prohibited)
Clinical signs
- Dry, red, scaly skin – typically on the back of the hand and between fingers
- No blisters or vesicles (distinguishes from ACD)
- Improvement with rest and moisturising treatment
Clinical significance
ICD should not be trivialised: compromised skin barrier increases the risk of sensitisation to accelerators and latex proteins. ICD can thus be the "entry point" to true allergy.
What the sales person should advise
- Correct size (too small → more friction)
- Powder-free gloves (now standard in medical use)
- Frequent use of hand cream
- Correct change frequency (avoid long continuous glove periods)
Type IV allergy – allergic contact dermatitis (ACD)
Type IV is the most common immunological glove reaction in healthcare and the reason why accelerator-free gloves have become standard in many hospitals.
Mechanism
Type IV allergy is a T-cell mediated delayed hypersensitivity reaction:
1. Sensitisation phase (initial exposure phase): Allergen (accelerator) penetrates the skin, binds to antigen-presenting cells (Langerhans cells), and T cells become sensitised. No symptoms in this phase.
2. Elicitation phase (on subsequent exposure): Sensitised T cells recognise the allergen and activate the inflammatory cascade → eczema.
Time pattern: 24–72 hours from contact to symptoms – crucial for distinguishing from Type I (minutes).
Most important accelerator allergens
Thiurams are the most common cause of ACD from gloves:
- TMTD (tetramethylthiuram disulfide) – most frequent
- TMTM, TETD
Dithiocarbamates:
- ZDEC, ZDBC – often cross-sensitise with thiurams (dithiocarbamates are metabolically related)
MBT and derivatives:
- MBT, MBTS, CBS – seen more frequently in industrial gloves
Guanidines:
- DPG (diphenylguanidine) – increasing incidence, used as a substitute for other accelerators
Diagnostics
Patch test is the gold standard:
- Standard series including thiurams, carbamates and MBT applied to the back for 48 hours
- Reading at 48 and 96 hours (delayed reaction)
- Performed by a dermatologist or occupational medicine specialist
Treatment and management
- Switch to accelerator-free nitrile gloves (documented per EN 455-5)
- Continued use of latex gloves may be possible with pure Type IV accelerator allergy (not Type I)
- Refer to a dermatologist if in doubt
Commercial relevance
ACD can be registered as an occupational disease and may lead to:
- Reporting to occupational disease authorities
- Employer responsibility for prevention
- Requirements for documented accelerator-free gloves from hospital procurement
Type I allergy – latex allergy
Type I latex allergy was in the 1990s a serious public health problem in healthcare. The powdering ban and transition to synthetic gloves have reduced the problem significantly.
Mechanism
Type I allergy is IgE-mediated (immediate type hypersensitivity):
1. Sensitisation: Latex proteins (Hev b antigens) stimulate B cells to produce IgE antibodies. IgE binds to mast cells.
2. Elicitation: On new exposure, latex protein cross-links IgE on mast cells → degranulation → histamine release → symptoms within minutes.
Hev b antigens
Over 13 Hev b proteins have been identified. The clinically most important are:
| Protein | Clinical relevance |
|---|---|
| Hev b 1 | High – primary sensitisation |
| Hev b 3 | High – cross-reacts with Ficus |
| Hev b 5 | High – correlates with clinical severity |
| Hev b 6.01/6.02 | High – frequent cause of anaphylaxis |
Clinical manifestations
- Contact urticaria: Hives directly at the skin contact site
- Rhinoconjunctivitis: Runny nose, eye irritation – particularly with powdered gloves (aerosol)
- Asthma: Bronchospasm – serious and grounds for occupational disease
- Anaphylaxis: Systemic reaction – can be life-threatening
Prevalence – history and today
| Population | Prevalence (historical) | Prevalence (today) |
|---|---|---|
| General population | ~1 % | ~1 % |
| Healthcare workers (1990s) | ~5–17 % | ~1–3 % |
| Latex-allergic individuals with spina bifida | Up to 40–65 % | Still high |
The fall in healthcare worker prevalence is directly linked to the phase-out of powdered latex gloves and increased use of synthetic materials.
The powdering ban and its effect
Following the EU Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) opinion from 2015, EU member states progressively prohibited powdered medical gloves from around 2016–2017. The US FDA implemented an equivalent ban effective 18 January 2017. Today powdered medical gloves are absent from both the EU and US markets.
The effect was significant: aerosol spread of latex protein via powdered starch disappeared, and new sensitisation cases have been drastically reduced.
Diagnostics
- ImmunoCAP/RAST: In vitro blood test measuring Hev b-specific IgE antibodies. Sensitive and can test specifically for Hev b proteins.
- Skin prick test: Latex extract applied to skin. Quick and cheap but requires specialist competence and preparedness for anaphylaxis.
What to do with documented Type I allergy
- Absolute contraindication to latex gloves (and all other latex equipment)
- Switch to synthetic alternative: nitrile, vinyl, polyisoprene, neoprene
- Employer has a duty to ensure a latex-free working environment for allergic employees
- Allergy documented in medical and occupational health records
- Be aware: latex is not only in gloves (catheters, masks, blood pressure cuffs, etc.)
Recommendations with documented allergy – quick guide
| Diagnosis | Recommended choice | What to avoid |
|---|---|---|
| Irritant contact dermatitis | Correct size, powder-free, frequent changes | Too small/large glove, prolonged use |
| Type IV ACD (accelerators) | Accelerator-free nitrile (EN 455-5 documented) | Standard nitrile with thiurams/dithiocarbamates |
| Type I latex allergy | Nitrile, vinyl, polyisoprene – NEVER latex | All latex gloves and latex-containing products |
| Type I + Type IV (both) | Accelerator-free nitrile or polyisoprene | Latex + standard nitrile with accelerators |
Commercial considerations: accelerator-free as a sales argument
Market arguments for accelerator-free nitrile:
1. Compliance requirements: Many hospitals and community health services require accelerator-free gloves as standard
2. Risk reduction: Reduces risk of ACD-related sick leave and occupational disease cases
3. Documentability: EN 455-5 provides an objective documentation framework
4. Broader applicability: Can be used by everyone – including those with accelerator allergy
Typical objection: "It is too expensive"
The counter-argument: The cost of ACD investigation (dermatologist, occupational medicine, sick leave, employee relocation) many times exceeds the price difference per glove. Calculate total cost of ownership – not just purchase price.